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Abstract
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Evidence exists for late-life depression (LLD) as both a prodrome of and risk factor for
Alzheimer’s disease (AD). The underlying neurobiological mechanisms are poorly understood.
Impaired peripheral glucose metabolism may explain the association between depression and AD
given the connection between type 2 diabetes mellitus with both depression and AD. Positron
emission tomography (PET) measures of cerebral glucose metabolism are sensitive to detecting
changes in neural circuitry in LLD and AD. Fasting serum glucose (FSG) in non-diabetic young
(YC; n=20) and elderly controls (EC; n=12) and LLD patients (n=16) was correlated with PET
scans of cerebral glucose metabolism on a voxel-wise basis. The negative correlations were more
extensive in EC versus YC and in LLD patients versus EC. Increased FSG correlated with
decreased cerebral glucose metabolism in LLD patients to a greater extent than in EC in
heteromodal association cortices involved in mood symptoms and cognitive deficits observed in
LLD and dementia. Negative correlations in YC were observed in sensory and motor regions.
Understanding the neurobiological consequences of diabetes and associated conditions will have
substantial public health significance given that this is a modifiable risk factor for which
prevention strategies could have an important impact on lowering dementia risk.
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1. Introduction
Late-life depression (LLD) has a substantial public health impact given its association with
serious disability, completed suicide, and mortality in the medically ill elderly (Henriksson
et al., 1995; Alexopoulos et al., 1996; Conwell et al., 1996). Cognitive impairment is a
common feature of LLD and often persists after mood symptom remission (Alexopoulos et
al., 1993; Alexopoulos et al., 1993; Bhalla et al., 2006). Furthermore, substantial evidence
suggests LLD is both a risk factor for and a prodrome of dementia. A meta-analysis
estimated that depression doubles the risk of subsequent Alzheimer’s disease (AD) (Ownby
et al., 2006). However, the mechanisms linking LLD to cognitive impairment and dementia
are poorly understood. Ultimately, understanding these mechanisms will allow for the
identification of individuals with LLD at increased risk for subsequent cognitive decline and
identification of treatment targets to prevent or delay transition to dementia.
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Abnormal glucose metabolism may represent a mechanistic link between LLD and dementia
(Rasgon and Jarvik, 2004). Individuals with type 2 diabetes mellitus (DM) have elevated
rates of AD and vascular dementia (Schmidt et al., 1992; Pasquier et al., 2006). Depression
approximately doubles the risk for future development of type 2 DM (Eaton et al., 1996).
Though hyperglycemia defines DM, hyperglycemia is not an immediate feature of insulin
resistance, which is the underlying pathophysiologic abnormality of type 2 DM. When an
individual develops insulin resistance, the pancreas initially increases insulin production to
maintain euglycemia. Ultimately, insulin resistance overwhelms the compensatory insulin
response and hyperglycemia develops. Insulin resistance is a continuous process. However,
diabetes and “pre-diabetes” (impaired glucose tolerance and impaired fasting glucose) are
diagnosed only by measured hyperglycemia (American Diabetes Association, 2013). Of
note, some depressed individuals manifest insulin resistance (Nathan et al., 1981; MennaPerper et al., 1984; Winokur et al., 1988; Okamura et al., 2000; Hennings et al., 2010) which
improves with depression treatment (Nathan et al., 1981; Okamura et al., 2000; Hennings et
al., 2010; Mueller et al., 1969; Weber-Hamann et al., 2008).
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Positron emission tomography (PET) studies of cerebral glucose metabolism demonstrate
sensitivity to detecting changes in neural circuitry associated with depression and dementia,
as well as in individuals at genetic risk for AD (Reiman et al., 1996; Mayberg et al., 2000;
Smith et al., 2009a; Smith et al., 2009b; Diaconescu et al., 2011). In cognitively normal
adults with “pre-diabetes” or early type 2 DM, Baker et al. showed that greater insulin
resistance was associated with an AD-like pattern of reduced cerebral glucose metabolism
(Baker et al., 2011). In healthy subjects (age range 47-68 years), Burns et al. reported a
correlation between higher fasting serum glucose (FSG) and lower cerebral glucose
metabolism in regions affected in AD. This correlation was stronger in individuals carrying
the APOE 4 allele, an AD risk factor (Burns et al., 2013). Thus, even in cognitively normal
subjects, higher FSG may be associated with vulnerability to AD-like changes in cerebral
glucose metabolism.
The present analyses correlated FSG with cerebral glucose metabolism in non-diabetic
young controls (YC) and elderly controls (EC) as well as non-diabetic LLD patients. The
hypotheses tested were: 1) Increased FSG will correlate with decreased cerebral glucose
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metabolism in LLD patients. The negative correlations will be observed in frontal and
parietal heteromodal association cortices which are associated with mood and cognitive
symptoms in LLD, and also demonstrate decreased cerebral glucose metabolism and
neuropathology in AD (neurofibrillary tangles and amyloid plaques). These areas include
the anterior cingulate, middle frontal, posterior cingulate, precuneus, and fusiform gyri
(Smith et al., 2009b; Diaconescu et al., 2011; Arnold et al., 1991; Langbaum et al., 2009). 2)
The negative correlations will be greater in the LLD patients than the EC in frontal and
parietal association cortices. 3) The negative correlations will be greater in the EC compared
to the YC in frontal and parietal association cortices.

2. Methods
2.1 Subject screening and selection

Author Manuscript

LLD patients, EC and YC subjects underwent psychiatric evaluation including a structured
clinical interview (First et al., 1995), laboratory testing (including complete blood count,
blood chemistry including screening glucose level, thyroid function tests, and toxicology
screening), and brain magnetic resonance (MR) imaging scan (GE 1.5T Magnetom Vision)
prior to the PET scans. The subjects were enrolled in a study to evaluate the acute effects of
the antidepressant citalopram on cerebral glucose metabolism. The data for the baseline
(placebo) PET scans in the LLD patients and controls have been published previously
(Smith et al., 2009a; Smith et al., 2009b; Goldberg et al., 2004).
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The sample included 16 older adults who met DSM-IV criteria for current major depressive
episode as well as 20 YC and 12 EC subjects who did not meet DSM-IV criteria for current
or past Axis I psychiatric disorders (as shown in Table 1). None of the participants had a
prior diagnosis of diabetes mellitus or screening laboratory values consistent with diabetes
mellitus (i.e. random blood glucose ≥ 200 mg/dl, fasting blood glucose ≥ 126 mg/dl).
Exclusion criteria were: past or current neurological disorder, other Axis I psychiatric
disorder (including substance abuse), lack of medical stability (including uncontrolled
hypertension), and use of a centrally acting medication or supplement within the past 2
weeks (including beta blockers, benzodiazepines, antihistamines, and cold medications). All
subjects were scanned on two consecutive days after an infusion of either placebo (250ml of
saline; scan 1) or citalopram (40mg of the drug diluted in 250ml saline; scan 2) over 60
minutes (Smith et al., 2009a). For the present study, only the PET scans following placebo
infusions were included in the analysis, before the citalopram was administered.
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Thirteen of the LLD patients had never been treated with psychotropic medications
(including antidepressants and antipsychotics). Of the remaining three patients, two took
sertraline prior to study entry (stopped 6 months to 2 years prior to enrollment). The third
patient took nortriptyline for 2 years up until 2 weeks prior to the PET scan (at which time
the plasma nortriptyline concentrations were undetectable). None of the patients took
citalopram previously. After a complete study description to potential participants, written
informed consent was obtained according to procedures established by the Institutional
Review Board and the Radiation Safety Committee of the North Shore-Long Island Jewish
Health System.
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PET scans were performed using a GE Advance Tomograph in the Center for
Neurosciences, Feinstein Institute for Medical Research, as described previously (Smith et
al., 2009a; Smith et al., 2009b; Diaconescu et al., 2011). All PET studies began at the same
time of day (10 AM). Subjects were instructed not to eat after midnight the evening before
the scans. Upon arrival at the PET facility, subjects received one intravenous catheter in the
left arm for radiotracer infusion and a second catheter in the right arm for sampling of
glucose and citalopram levels. Five mCi of [18F]-2-deoxy-2-fluoro-D-glucose ([18F]-FDG)
was injected as an intravenous bolus. The FSG determined at this time was used for the
correlation analyses. During the [18F]-FDG uptake interval, the subjects sat in a darkened,
quiet room with eyes open and ears unoccluded. At 25 minutes after radiotracer injection,
subjects were positioned in the GE Advance Tomograph. A 10 minute transmission scan and
a 5 minute two-dimensional emission scan were acquired first to perform photon attenuation
correction. A three-dimensional emission scan began 40 minutes after radiotracer injection
and lasted for 10 minutes. At the end of the scan, subjects were debriefed as to their
perceptions of the study.
2.3 Data and image analysis
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Glucose metabolic rates were calculated (in ml/100g/min) on a voxel-wise basis according
to validated methods (Takikawa et al., 1993). PET data processing was performed on the
quantitative glucose metabolism images using the Statistical Parametric Mapping program
(SPM5, Institute of Neurology, London). This is a data driven analytic approach that
performs statistical tests on each voxel in the image. In summary, for each subject, all PET
scans were realigned using a generated mean image (the placebo scan 1 was used for the
analyses in this article). The PET scans were normalized to the SPM5 PET template in
Montreal Neurological Institute (MNI) space and then smoothed with an isotropic Gaussian
kernel (full width at half maximum 8mm for all directions). The glucose metabolic rates
were normalized by scaling to a common mean value (50) across all scans, after establishing
that the global means did not differ significantly between and within groups at each time
point (p > 0.05). The data were normalized to a global mean because of the greater testretest variability for absolute compared to relative glucose metabolism observed in
numerous studies (e.g. (Bartlett et al., 1988)). Voxel-wise correlations between FSG and
cerebral glucose metabolism were performed for the EC, EC and LLD patients separately
using the one sample t-tests option with FSG as a covariate in SPM5. Then, the correlations
were compared between groups with the two-sample t-test option with FSG as a covariate.
Representative design matrices for the two analysis methods are provided as supplemental
material. The two comparisons performed were the YC versus the EC and the EC versus
LLD. To control for multiple comparisons, both probability level and cluster size thresholds
were used. The comparisons were considered significant at a t threshold greater than 2.98 (z
> 2.58, p < 0.005; uncorrected for multiple independent comparisons) and at a
predetermined cluster size greater than 100 voxels.
The comparisons that were also significant at the at the uncorrected cluster level are
indicated (p < 0.05). The results were not significant when corrected for multiple
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comparisons. The significance level reported was similar to recent studies that showed an
association between FSG and glucose metabolism (Burns et al., 2013).

3. Results
3.1 Subject characteristics
The demographic characteristics and FSG at the time of PET scanning for YC, EC and LLD
patients appear in Table 1. The YC were significantly younger than the EC and LLD
patients (p < 0.01), but the EC and LLD patients did not differ significantly in age (p > 0.1).
The three groups did not differ significantly in years of education, FSG or body mass index
(BMI) (p>0.1). The EC and LLD patients did not differ significantly in global cognitive
function (p > 0.1) as measured by the Mini-Mental Status Examination (MMSE) and the
Dementia Rating Scale (DRS) (Folstein et al., 1975; Mattis, 1976).
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Correlations of FSG with age, BMI, depressive symptoms, cognition (California Verbal
Learning Test [CVLT], verbal fluency) were not significant within groups. Thus, these
variables were not used in the statistical analyses. Gender was correlated with BMI in the
LLD patients and with FSG in the EC only. Because a systematic relationship of gender
with BMI and FSG was not observed across groups, gender was not included as a covariate.
3.2 YC (Table 2a)
Positive correlations between FSG and cerebral glucose metabolism were observed in the
right lingual gyrus (Brodmann area (BA) 18). Negative correlations were observed in the
medial frontal gyrus (BA 6 bilaterally, left BA 10), left precentral gyrus (BA 6), right
superior temporal gyrus (BA 22) and left putamen.
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3.3 EC (Table 2b)
Positive correlations were observed in the left middle frontal gyrus (BA 8), left medial
frontal gyrus (BA 6) and left inferior parietal lobule (BA 40). Negative correlations were
observed in the left anterior cingulate gyrus (BA 32), right middle frontal gyrus (BA 6),
right precentral gyrus (BA 4), left superior temporal gyrus (BA 42), right posterior cingulate
gyrus (BA 31) and right precuneus (BA 7).
3.4 LLD Patients (Table 2c and Fig. 1)
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There were no positive correlations observed in the LLD patients. Negative correlations
were observed in the right medial frontal gyrus (BA 10), right inferior frontal gyrus (BA 47),
left precentral gyrus (BA 6), left superior temporal gyrus (BA 42), right inferior parietal
lobule (BA 40) and bilateral fusiform gyrus (BA 37).
3.5 Comparison of EC versus YC (Table 3a)
Greater positive correlations in the EC than YC were observed in the right insula (BA 13),
bilateral middle frontal gyrus (BA 8/6), left putamen and left inferior parietal lobule (BA
40). Greater negative correlations in the EC than YC were observed in the right inferior
frontal gyrus (BA 9), right precentral gyrus (BA 4), right precuneus (BA 7) and right
fusiform gyrus (BA 37).
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3.6 Comparison of LLD Patients versus EC (Table 3b)
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Greater positive correlations in the LLD patients than the EC were observed in the right
postcentral gyrus (BA 3). Greater negative correlations in the LLD patients than the EC
were observed in the bilateral middle frontal gyrus (BA 8), left putamen, right insula (BA
13) and left fusiform gyrus (BA 37).

4. Discussion

Author Manuscript

In the present study, in the YC, negative correlations between cerebral glucose metabolism
and FSG were observed mainly in primary sensory (auditory cortex) and motor (pre-central
gyrus and putamen) areas. A positive correlation was observed for visual association cortex
and a negative correlation for middle frontal gyrus. In the EC, positive correlations were
observed in medial frontal gyrus and inferior parietal lobule. Negative correlations were
observed in both primary sensory (auditory) and motor cortex as well as frontal and parietal
association cortices (anterior cingulate, middle frontal, posterior cingulate, and precuneus).
In the LLD patients, similar to the EC subjects, negative correlations were observed in both
primary sensory (auditory) and motor cortices as well as frontal and parietal association
cortices (middle and inferior frontal, inferior parietal lobule and precuneus).
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The results are consistent with the primary study hypotheses of greater negative correlations
in frontal and parietal association cortices in EC compared to YC and LLD compared to EC.
While the correlations in the YC were mainly observed in sensory and motor regions, the
correlations in EC and LLD patients were observed mainly in heteromodal association
cortices involved in depressive symptoms and cognitive functions (attention, memory,
visuo-spatial processing) affected in LLD and AD as shown by PET studies of glucose
metabolism in LLD and AD and in neuropathological studies in AD (Smith et al., 2009b;
Diaconescu et al., 2011; Arnold et al., 1991). Several results were unexpected. In all groups,
negative correlations in both primary sensory (auditory cortex) and motor cortex were
observed. Secondly, positive correlations were observed, to a greater extent in EC than YC,
in areas involved in attention and affective processing that may indicate a compensatory
response. Interestingly, these positive correlations are not observed in the untreated LLD
patients.

Author Manuscript

The results in EC are consistent with the findings of Burns et al (Burns et al., 2013). The
investigators reported correlations between higher FSG levels and lower cerebral glucose
metabolism in temporal and parietal cortical regions that show reductions in cerebral
glucose metabolism in AD. In their study, the correlations were greater in APOE4 carriers
than controls without an APOE4 allele. The results of the present study replicate these
findings and extend these observations to YC and EC and to LLD, a condition also
associated with increased risk of cognitive decline.
Importantly, study participants were not diabetic. Therefore, cerebral glucose metabolism
data could be interpreted without the potential confound of significant fluctuation in FSG
during the PET scan. It is noteworthy that significant associations between cerebral
metabolism and FSG were obtained within this restricted range of values (highest value 113
mg/dL). Also of note, the EC and LLD patients did not meet criteria for mild cognitive
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impairment or AD and performed within the normal range in dementia scales, as well as
specific cognitive tests of verbal and visuo-spatial memory, attention and executive function
(data not shown). Further, the cognitive tests were not correlated with FSG (data not shown).
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The association between higher FSG and lower glucose metabolism in heteromodal
association vulnerable areas affected in AD is consistent with the observations that diabetes
and associated risk factors (e.g. hyperglycemia, hyperinsulinemia, insulin resistance) are
associated with increased risk of AD (Haan, 2006). The biological mechanisms that underlie
how diabetes increases the risk and accelerates the progression of AD are an active area of
investigation. There are numerous potential mechanisms associated with diabetes and related
conditions that could be associated with increased dementia risk (and decreased glucose
metabolism). For instance, insulin resistance is directly implicated in AD pathology via both
increased amyloid-beta and tau hyperphosphorylation (Craft and Watson, 2004).
Furthermore, intranasal insulin is a promising potential treatment for AD as evidenced by
recent clinical trials (Reger et al., 2006; Dhamoon et al., 2009; Craft et al., 2012). Other
potential mechanisms include activation of mitogen activated protein kinase (MAPK) and
Akt signaling pathways, inflammation and increased oxidative stress combined with
increased intracellular calcium that could result in mitochondrial damage and neuronal death
(for review, see (Sims-Robinson et al., 2010)).
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The same two mechanisms that might explain insulin resistance-induced cognitive
impairment are also the same pathophysiologies that may explain cognitive impairment in
LLD, i.e. Alzheimer’s and vascular pathologies. First, LLD may represent, in some cases, an
AD prodrome as the first non-cognitive manifestation of Alzheimer’s pathology. Second, as
articulated in the vascular depression hypothesis, brain vascular disease underlies the
pathophysiology of LLD including associated cognitive impairment (Alexopoulos et al.,
1997; Krishnan et al., 1997). Furthermore, executive dysfunction is a frequent domain of
cognitive impairment in both LLD and insulin resistance, and is associated with vascular
pathology in LLD, particularly damage to frontostriatal circuits (Alexopoulos, 2001;
Abbatecola et al., 2004). Thus, insulin resistance, through both vascular and Alzheimer’s
pathologies, may represent a modifiable mechanism underlying the increased risk of
cognitive decline in LLD.
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It is important to note that insulin resistance does not necessarily result in hyperglycemia, at
least in its early stages. In the present study, we did not measure insulin resistance, which is
a study limitation. However, significant associations between cerebral metabolism and FSG
were obtained within a restricted range of FSG. Though we do not know if subjects in the
study manifest insulin resistance, our findings suggest that individuals who demonstrate
elevated FSG may be vulnerable to lower cerebral glucose metabolism in regions implicated
in AD and cognitive status should be followed more closely.
Given that the participants in the study were not diabetic, outside of undetected insulin
resistance, another possible explanation for the negative correlation between cerebral
glucose metabolism and FSG in selected brain regions is that these regions may be
particularly vulnerable to variations in peripheral glucose concentrations. This differential
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sensitivity could have implications for areas first affected by insulin resistance mediated AD
pathology, though further study is needed.
Study limitations include: the lack of APOE genotyping and the lack of additional measures
of peripheral glucose metabolism (such as fasting insulin levels). Fasting insulin levels
would have allowed us to estimate insulin resistance and, thus, correlate insulin resistance
and cerebral glucose metabolism. APOE genotype appears to affect insulin metabolism in
AD patients (Craft et al., 1999), as well as cognitive response to intranasal insulin (Reger et
al., 2006). While we did not observe correlations of FSG with age, BMI, depressive
symptoms or cognition (California Verbal Learning Test [CVLT], verbal fluency) within
groups, the possibility still exists that that the association between fasting glucose and
regional metabolism is mediated by one of these variables.
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Future studies will use multi-modality imaging methods with more direct measures of
Alzheimer pathology (such as brain amyloid) and vascular pathology (such as MR white
matter hyperintensities) as well as more sensitive measures of peripheral glucose
metabolism and insulin resistance (such as the oral glucose tolerance test) to better
characterize the relationship between impaired glucose metabolism, depression, and
dementia. Understanding the neurobiological consequences of diabetes and associated
conditions will have substantial public health significance given that this is a modifiable risk
factor for which prevention strategies could have an important impact on lowering dementia
risk.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.

Negative correlation between FSG and Cerebral Glucose Metabolism in LLD Patients
A and B: Bi-lateral Fusiform Gyrus (BA 37); C: Right Inferior Frontal Gyrus (BA 47); D:
Right Medial Frontal Gyrus (BA 10); E: Left Superior Temporal Gyrus (BA 42); F: Right
Inferior Parietal Lobule (BA 40); G: Left Precentral Gyrus (BA 6)
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